Literature DB >> 12594285

CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell.

Jeffrey J Roszkowski1, David C Yu, Mark P Rubinstein, Mark D McKee, David J Cole, Michael I Nishimura.   

Abstract

The CD8 coreceptor enhances T cell function by stabilizing the TCR/peptide/MHC complex and/or increasing T cell avidity via interactions with the intracellular kinases Lck and LAT. We previously reported a CD4(+) T cell (TIL 1383I), which recognizes the tumor-associated Ag tyrosinase in the context of HLA-A2. To determine whether CD8 independent tumor cell recognition is a property of the TCR, we used retroviral transduction to express the TIL 1383I TCR in the CD8(-) murine lymphoma, 58 alpha(-)/beta(-). Immunofluorescent staining of TCR-transduced cells with human TCR V beta subfamily-specific and mouse CD3-specific Abs confirmed surface expression of the transferred TCR and coexpression of mouse CD3. Transduced effector cells secreted significant amounts of IL-2 following Ag presentation by tyrosinase peptide-pulsed T2 cells as well as stimulation with HLA-A2(+) melanoma lines compared with T2 cells alone or HLA-A2(-) melanoma cells. Further analysis of TCR-transduced clones demonstrated a correlation between T cell avidity and cell surface expression of the TCR. Therefore, the TIL 1383I TCR has sufficient affinity to mediate recognition of the physiologic levels of Ag expressed by tumor cells in the absence of CD8 expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594285     DOI: 10.4049/jimmunol.170.5.2582

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  T cell receptor-transgenic primary T cells as a tool for discovery of leukaemia-associated antigens.

Authors:  R Ivanov; S Hol; T I Aarts; A Hagenbeek; S B Ebeling
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

2.  Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.

Authors:  Ralf-Holger Voss; Jürgen Kuball; Renate Engel; Philippe Guillaume; Pedro Romero; Christoph Huber; Matthias Theobald
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

3.  Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.

Authors:  Richard C Koya; Stephen Mok; Begoña Comin-Anduix; Thinle Chodon; Caius G Radu; Michael I Nishimura; Owen N Witte; Antoni Ribas
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

4.  Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.

Authors:  Yangbing Zhao; Zhili Zheng; Paul F Robbins; Hung T Khong; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2005-04-01       Impact factor: 5.422

5.  Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes.

Authors:  Laura A Johnson; Bianca Heemskerk; Daniel J Powell; Cyrille J Cohen; Richard A Morgan; Mark E Dudley; Paul F Robbins; Steven A Rosenberg
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

6.  Adoptive immunotherapy of cancer: Gene transfer of T cell specificity.

Authors:  Amir A Al-Khami; Shikhar Mehrotra; Michael I Nishimura
Journal:  Self Nonself       Date:  2011-04-01

7.  CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Authors:  Håkan Norell; Yi Zhang; James McCracken; Telma Martins da Palma; Aaron Lesher; Yueying Liu; Jeffrey J Roszkowski; Anquanette Temple; Glenda G Callender; Timothy Clay; Rimas Orentas; José Guevara-Patiño; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2010-01-06       Impact factor: 6.968

8.  Human antigen-specific regulatory T cells generated by T cell receptor gene transfer.

Authors:  Todd M Brusko; Richard C Koya; Shirley Zhu; Michael R Lee; Amy L Putnam; Stephanie A McClymont; Michael I Nishimura; Shuhong Han; Lung-Ji Chang; Mark A Atkinson; Antoni Ribas; Jeffrey A Bluestone
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

Review 9.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

10.  High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.

Authors:  Richard A Morgan; Mark E Dudley; Yik Y L Yu; Zhili Zheng; Paul F Robbins; Marc R Theoret; John R Wunderlich; Marybeth S Hughes; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.